Merus
(https://merus.nl) 📸 Data Snapshot: May 24, 2026Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Authority is primarily established through technical jargon and trial references rather than named human experts. The data reveals a lack of specific leadership or scientific board names (Person schema is missing), which creates an ‘anonymous corporate’ profile. The technical implementation is professional with clean JSON-LD, though the reliance on external Genmab links for current data indicates a loss of local site authority.
The marketing tone ‘Closing in on Cancer’ is a bold emotive claim, but it is backed by the mention of ‘Phase 3 registrational trials,’ which is the highest level of pre-market proof in this industry. The disconnect is minor, primarily existing in the gap between the ‘urgency’ claimed on the homepage and the reality of long-term clinical trial timelines. The transition to Genmab further complicates the ‘Our Pipeline’ performance claims.
Identity & Authority is read from the structured data first: whether the site declares who it is in machine-readable schema, with verifiable identity links. Below is the schema captured per page, then the external proof links that support (or fail to support) that identity.
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps
Homepage schema
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebSite",
"@id": "https://merus.nl/#/schema/WebSite",
"url": "https://merus.nl/",
"name": "Merus",
"description": "Closing in on cancer",
"inLanguage": "en-US",
"potentialAction": {
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://merus.nl/search/{search_term_string}/"
},
"query-input": "required name=search_term_string"
},
"publisher": {
"@id": "https://merus.nl/#/schema/Organization"
}
},
{
"@type": "WebPage",
"@id": "https://merus.nl/",
"url": "https://merus.nl/",
"name": "Closing in on cancer | Merus",
"description": "At Merus, we know that time is of the essence. Every day, we bring a sense of urgency and a passion to help patients, by working towards discovering and…",
"inLanguage": "en-US",
"isPartOf": {
"@id": "https://merus.nl/#/schema/WebSite"
},
"breadcrumb": {
"@type": "BreadcrumbList",
"@id": "https://merus.nl/#/schema/BreadcrumbList",
"itemListElement": {
"@type": "ListItem",
"position": 1,
"name": "Merus"
}
},
"potentialAction": {
"@type": "ReadAction",
"target": "https://merus.nl/"
},
"about": {
"@id": "https://merus.nl/#/schema/Organization"
}
},
{
"@type": "Organization",
"@id": "https://merus.nl/#/schema/Organization",
"name": "Merus",
"url": "https://merus.nl/"
}
]
}
/about/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebSite",
"@id": "https://merus.nl/#/schema/WebSite",
"url": "https://merus.nl/",
"name": "Merus",
"description": "Closing in on cancer",
"inLanguage": "en-US",
"potentialAction": {
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://merus.nl/search/{search_term_string}/"
},
"query-input": "required name=search_term_string"
},
"publisher": {
"@type": "Organization",
"@id": "https://merus.nl/#/schema/Organization",
"name": "Merus",
"url": "https://merus.nl/"
}
},
{
"@type": "WebPage",
"@id": "https://merus.nl/about/",
"url": "https://merus.nl/about/",
"name": "About Us | Merus",
"description": "At Merus, we are clinically advancing leading-edge, targeted treatments to address the unmet needs of patients with various types of cancer.",
"inLanguage": "en-US",
"isPartOf": {
"@id": "https://merus.nl/#/schema/WebSite"
},
"breadcrumb": {
"@type": "BreadcrumbList",
"@id": "https://merus.nl/#/schema/BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"item": "https://merus.nl/",
"name": "Merus"
},
{
"@type": "ListItem",
"position": 2,
"name": "About Us"
}
]
},
"potentialAction": {
"@type": "ReadAction",
"target": "https://merus.nl/about/"
}
}
]
}
/technology/multiclonics-platform/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebSite",
"@id": "https://merus.nl/#/schema/WebSite",
"url": "https://merus.nl/",
"name": "Merus",
"description": "Closing in on cancer",
"inLanguage": "en-US",
"potentialAction": {
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://merus.nl/search/{search_term_string}/"
},
"query-input": "required name=search_term_string"
},
"publisher": {
"@type": "Organization",
"@id": "https://merus.nl/#/schema/Organization",
"name": "Merus",
"url": "https://merus.nl/"
}
},
{
"@type": "WebPage",
"@id": "https://merus.nl/technology/multiclonics-platform/",
"url": "https://merus.nl/technology/multiclonics-platform/",
"name": "Multiclonics® Platform | Merus",
"description": "Our Multiclonics® therapeutics are produced from our proprietary technology platforms, which are able to generate a diverse array of antibody binding domains…",
"inLanguage": "en-US",
"isPartOf": {
"@id": "https://merus.nl/#/schema/WebSite"
},
"breadcrumb": {
"@type": "BreadcrumbList",
"@id": "https://merus.nl/#/schema/BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"item": "https://merus.nl/",
"name": "Merus"
},
{
"@type": "ListItem",
"position": 2,
"item": "https://merus.nl/technology/",
"name": "Technology"
},
{
"@type": "ListItem",
"position": 3,
"name": "Multiclonics® Platform"
}
]
},
"potentialAction": {
"@type": "ReadAction",
"target": "https://merus.nl/technology/multiclonics-platform/"
}
}
]
}
/pipeline/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebSite",
"@id": "https://merus.nl/#/schema/WebSite",
"url": "https://merus.nl/",
"name": "Merus",
"description": "Closing in on cancer",
"inLanguage": "en-US",
"potentialAction": {
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://merus.nl/search/{search_term_string}/"
},
"query-input": "required name=search_term_string"
},
"publisher": {
"@type": "Organization",
"@id": "https://merus.nl/#/schema/Organization",
"name": "Merus",
"url": "https://merus.nl/"
}
},
{
"@type": "WebPage",
"@id": "https://merus.nl/pipeline/",
"url": "https://merus.nl/pipeline/",
"name": "Pipeline | Merus",
"description": "You can find the latest information on our pipeline on the Genmab Pipeline page https://www.genmab.com/antibody-science/",
"inLanguage": "en-US",
"isPartOf": {
"@id": "https://merus.nl/#/schema/WebSite"
},
"breadcrumb": {
"@type": "BreadcrumbList",
"@id": "https://merus.nl/#/schema/BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"item": "https://merus.nl/",
"name": "Merus"
},
{
"@type": "ListItem",
"position": 2,
"name": "Pipeline"
}
]
},
"potentialAction": {
"@type": "ReadAction",
"target": "https://merus.nl/pipeline/"
}
}
]
}
🛡️ Trust Signals — external proof links that back the declared identity
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 2 | 0 |
| /about/ | 2 | 0 |
| /technology/multiclonics-platform/ | 3 | 0 |
| /pipeline/ | 2 | 0 |
This page presents a snapshot of public data from Merus, captured on May 24, 2026, to show how machine logic reads Identity & Authority signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Merus: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://merus.nl to view the most current version of its content and see directly what this company is about and what it offers.